Elicio raises $15M to push its pancreatic cancer immunotherapy forward
What's the deal? Elicio TherapeuticsDealroom has a profile for this one. Try Dealroom → (Nasdaq: ELTX) has priced a $15 million registered direct offering, selling 4.38 million shares to two institutional investors and a large existing shareholder.
The raise closes July 6, 2026. Proceeds will fund Phase 1 development of ELI-002, its treatment for metastatic pancreatic ductal adenocarcinoma (PDAC), plus other pipeline work.
Why now? Elicio held just $18.6 million in cash at the end of 2025, against a $39.5 million net loss for the year.
The fresh capital arrives as the company nears a key milestone: results from its Phase 2 AMPLIFY-7P trial of ELI-002 7P, with the primary disease-free survival analysis expected in the first half of 2026.
The money also supports a new Phase 1 study at Memorial Sloan Kettering Cancer Center, funded by the Lustgarten Foundation, set to begin enrolling in H1 2026.
What could go wrong? Elicio remains blinded to the trial's efficacy results, so the outcome is unknown. It has, however, observed fewer disease progressions and deaths than projected so far.
Pancreatic cancer is notoriously hard to treat, and a single trial readout could sway the company's future.
The signal: Elicio's Amphiphile platform aims to re-engineer the body's immune response to cancer by amplifying tumour-specific T cells, positioning the late-stage biotech within a crowded but promising KRAS-targeting field. With the modest raise stretching an $18.6 million cash pile, the offering effectively buys just enough runway to reach the pivotal AMPLIFY-7P readout that will define the company's next chapter.
Read more: AInvest
Image credit: Generated with Gemini
